26.95
전일 마감가:
$30.35
열려 있는:
$28.49
하루 거래량:
811.03K
Relative Volume:
4.56
시가총액:
$176.79M
수익:
-
순이익/손실:
$-74.14M
주가수익비율:
-2.3661
EPS:
-11.39
순현금흐름:
$-65.70M
1주 성능:
+28.21%
1개월 성능:
+129.95%
6개월 성능:
+0.15%
1년 성능:
+144.11%
인스틸 바이오 Stock (TIL) Company Profile
명칭
Instil Bio Inc
전화
(972) 499-3350
주소
3963 MAPLE AVENUE, DALLAS
TIL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
TIL
Instil Bio Inc
|
26.95 | 137.89M | 0 | -74.14M | -65.70M | -11.39 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
인스틸 바이오 Stock (TIL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-01-07 | 업그레이드 | Jefferies | Hold → Buy |
2024-11-04 | 개시 | JMP Securities | Mkt Perform |
2024-04-12 | 다운그레이드 | Jefferies | Buy → Hold |
2022-11-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
2022-11-01 | 다운그레이드 | Truist | Buy → Hold |
2021-08-13 | 개시 | Robert W. Baird | Outperform |
2021-04-13 | 개시 | Cowen | Outperform |
2021-04-13 | 개시 | Morgan Stanley | Equal-Weight |
2021-04-13 | 개시 | Truist | Buy |
모두보기
인스틸 바이오 주식(TIL)의 최신 뉴스
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Instil Bio CEO Reveals Latest Pipeline Updates at Prestigious Jefferies Healthcare Conference - Stock Titan
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - sharewise
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - sharewise
Instil Bio Elects Director and Ratifies Auditor - TipRanks
Instil Bio Advances Phase 2 Trial in China - TipRanks
(TIL) Proactive Strategies - news.stocktradersdaily.com
Instil Bio: Second Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success (TIL) - Seeking Alpha
H.C. Wainwright lifts Instil Bio stock target to $125 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Instil Bio stock target to $125 - Investing.com
Instil Bio (TIL) Receives Price Target Upgrade by HC Wainwright & Co. | TIL Stock News - GuruFocus
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following P - GuruFocus
Instil Bio and ImmuneOnco to Host Investor and Analyst - GlobeNewswire
Instil Bio and ImmuneOnco Announce Joint Investor Breakfast in Chicago to Discuss Immuno-Oncology Developments - Nasdaq
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving ... - Bluefield Daily Telegraph
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following Positive Data Release | TIL Stock News - GuruFocus
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | - GuruFocus
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in - GlobeNewswire
Instil Bio (TIL) Shares Surge on New Clinical Development Plans - GuruFocus
Instil Bio stock rises on cancer trial updates (TIL:NASDAQ) - Seeking Alpha
Instil Bio (TIL) Maintains Buy Rating as Price Target is Adjusted | TIL Stock News - GuruFocus
Instil Bio stock price target cut to $105 by H.C. Wainwright - Investing.com Nigeria
Instil Bio (TIL) Price Target Reduced by Analyst | TIL Stock News - GuruFocus
Instil Bio Partners with ImmuneOnco for Cancer Therapy - TipRanks
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | TIL Stock News - GuruFocus
Alerts incorrectly tagged to T Rowe Price Large-Cap Value Fund withdrawn - marketscreener.com
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ... - Bluefield Daily Telegraph
Instil Bio's Lung Cancer Drug Achieves 23% Response Rate in Phase 2 Trial, Major Results Expected in Late 2025 - Stock Titan
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
(TIL) Investment Analysis - news.stocktradersdaily.com
Instil (TIL) Projects Financial Stability Through 2026 | TIL Sto - GuruFocus
Instil Bio, Inc. SEC 10-Q Report - TradingView
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Instil Bio Inc expected to post a loss of $2.59 a shareEarnings Preview - TradingView
Trading (TIL) With Integrated Risk Controls - news.stocktradersdaily.com
Financial Metrics Check: Microbot Medical Inc (MBOT)’s Ratios for Trailing Twelve Months - DWinneX
Investor’s Toolkit: Key Ratios for Assessing Instil Bio Inc (TIL)’s Performance - DWinneX
TIL’s Stock Market Adventure: -33.05% YTD Growth Amidst Volatility - investchronicle.com
Have you been able to find a good deal on Instil Bio Inc’s shares? - uspostnews.com
Instil Bio Inc (TIL) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
(TIL) Trading Report - news.stocktradersdaily.com
Here's Why Summit Therapeutics Stock Soared 15% on Friday - Nasdaq
GT’s Debt-to-Equity Ratio at 1.85: What It Means for Goodyear Tire & Rubber Co’s Future - investchronicle.com
Where are the Opportunities in (TIL) - news.stocktradersdaily.com
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway Globally - GlobeNewswire Inc.
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market - GlobeNewswire
SEC Form 424B5 filed by Instil Bio Inc. - Quantisnow
(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
The Significance of Moving Averages in New Found Gold Corp Inc. (NFGC) Price Performance - investchronicle.com
인스틸 바이오 (TIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):